Enveric Biosciences, Inc. (NASDAQ:ENVB)

Enveric Biosciences, Inc. ENVB

Healthcare - Biotechnology - NASDAQ - US

Watchlist

$ 0.365

-8.06 %

$ 3.26 M

Market Cap

-0.1

P/E

1. INTRINSIC VALUE

Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.[ Read More ]

The intrinsic value of one ENVB stock under the base case scenario is HIDDEN Compared to the current market price of 0.365 USD, Enveric Biosciences, Inc. is HIDDEN

ENVB Intrinsic Value
HIDDEN

SHOW

2. FUNDAMENTAL ANALYSIS

Price Chart ENVB

FINANCIALS

Annual
Quarterly

0 REVENUE

Growth Rates

1Year 0.00%

3Years 0.00%

5Years 0.00%

7Years 0.00%

10Years 0.00%

-16.4 M OPERATING INCOME

Growth Rates

1Year 40.00%

3Years -43.06%

5Years -18.14%

7Years -17.31%

10Years -89.73%

-17.3 M NET INCOME

Growth Rates

1Year 6.39%

3Years -36.06%

5Years -0.46%

7Years -29.83%

10Years -218.49%

-14.1 M OPERATING CASH FLOW

Growth Rates

1Year 17.80%

3Years -53.61%

5Years -40.60%

7Years -26.60%

10Years -91.16%

11.7 K INVESTING CASH FLOW

Growth Rates

1Year 102.00%

3Years 31.31%

5Years 14.91%

7Years 10.42%

10Years 0.00%

-1.34 M FINANCING CASH FLOW

Growth Rates

1Year -7.39%

3Years -524.73%

5Years -8.43%

7Years -2.05%

10Years -52.16%

0 REVENUE

Growth Rates

1Year 0.00%

3Years 0.00%

5Years 0.00%

7Years 0.00%

10Years 0.00%

-1.9 M OPERATING INCOME

Growth Rates

1Year 40.00%

3Years -43.06%

5Years -18.14%

7Years -17.31%

10Years -89.73%

-1.88 M NET INCOME

Growth Rates

1Year 6.39%

3Years -36.06%

5Years -0.46%

7Years -29.83%

10Years -218.49%

-2.89 M OPERATING CASH FLOW

Growth Rates

1Year 17.80%

3Years -53.61%

5Years -40.60%

7Years -26.60%

10Years -91.16%

0 INVESTING CASH FLOW

Growth Rates

1Year 102.00%

3Years 31.31%

5Years 14.91%

7Years 10.42%

10Years 0.00%

34.4 K FINANCING CASH FLOW

Growth Rates

1Year -7.39%

3Years -524.73%

5Years -8.43%

7Years -2.05%

10Years -52.16%

Balance Sheet Decomposition Enveric Biosciences, Inc.

4.3 M ASSETS
2.34 M LIABILITIES

Current Assets	3.58 M
Cash & Short-Term Investments	2.29 M
Receivables	225 K
Other Current Assets	1.07 M
Non-Current Assets	718 K
Long-Term Investments	0
PP&E	507 K
Other Non-Current Assets	211 K

Current Liabilities	2.34 M
Accounts Payable	1.22 M
Short-Term Debt	0
Other Current Liabilities	1.12 M
Non-Current Liabilities	0
Long-Term Debt	0
Other Non-Current Liabilities	0

EFFICIENCY

Earnings Waterfall Enveric Biosciences, Inc.

Revenue	0
Cost Of Revenue	408 K
Gross Profit	-408 K
Operating Expenses	16.4 M
Operating Income	-16.4 M
Other Expenses	843 K
Net Income	-17.3 M

RATIOS

0.00% GROSS MARGIN

Averages

1Year 0.00%

3Years 0.00%

5Years 4.08%

7Years 8.91%

10Years 11.65%

0.00% OPERATING MARGIN

Averages

1Year 0.00%

3Years 0.00%

5Years -3.17%

7Years -8.16%

10Years -8.37%

0.00% NET MARGIN

Averages

1Year 0.00%

3Years 0.00%

5Years -2.81%

7Years -10.29%

10Years -9.15%

-0.88% ROE

Averages

1Year -0.88%

3Years -115.45%

5Years -117.22%

7Years -112.83%

10Years -67.59%

-0.40% ROA

Averages

1Year -0.40%

3Years -92.72%

5Years -91.30%

7Years -75.84%

10Years -121.32%

-842.19% ROIC

Averages

1Year -842.19%

3Years -421.54%

5Years -292.29%

7Years -224.11%

10Years -74.03%

FREE CASH FLOW ANALYSIS

Free Cash Flow Analysis Enveric Biosciences, Inc.

Net Income	-17.3 M
Depreciation & Amortization	408 K
Capital Expenditures	-5.18 K
Stock-Based Compensation	2.15 M
Change in Working Capital	-175 K
Others	743 K
Free Cash Flow	-14.1 M

3. WALL STREET ANALYSTS ESTIMATES

Wall Street Analysts Price Targets Enveric Biosciences, Inc.

ENVB has no price targets from Wall Street.

4. DIVIDEND ANALYSIS

0.00% DIVIDEND YIELD

18.5 K USD DIVIDEND PER SHARE

5. COMPETITION

Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The company is developing mono-specific and bi-specific humanized monoclonal antibodies (mAb) product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome.

-0.0499 USD

OCEA

Overvalued 106.99%

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States.

3.67 USD

HEPA

Undervalued 439.85%

Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States.

0.561 USD

ELEV

Undervalued 5.55%

CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases.

2.04 USD

CWBR

Undervalued 298.62%

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.

3.02 USD

ZURA

Overvalued 4.48%

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer.

-2.09 USD

EFTR

Overvalued 1044932.22%

6. Ownership

Insider Ownership Enveric Biosciences, Inc.

Summary
Transactions

Sold

0-3 MONTHS

0 USD 0

3-6 MONTHS

0 USD 0

6-9 MONTHS

0 USD 0

9-12 MONTHS

0 USD 0

Bought

0 USD 0

0-3 MONTHS

0 USD 0

3-6 MONTHS

0 USD 0

6-9 MONTHS

0 USD 0

9-12 MONTHS

Date	Value	Insider	Amount	Avg Price
1 year ago Sep 15, 2023	Bought 2.14 K USD	PASQUALONE FRANK Director	+ 1000	2.14 USD
6 years ago Nov 16, 2018	Sell 17.6 USD	Sikaria Lokesh 10 percent owner	- 58	0.3028 USD
6 years ago Nov 16, 2018	Sell 452 USD	Sikaria Lokesh 10 percent owner	- 1500	0.3011 USD
6 years ago Nov 16, 2018	Sell 455 USD	Sikaria Lokesh 10 percent owner	- 1515	0.3006 USD
6 years ago Nov 16, 2018	Sell 4.24 K USD	Sikaria Lokesh 10 percent owner	- 14119	0.3003 USD
6 years ago Nov 16, 2018	Sell 4.58 K USD	Sikaria Lokesh 10 percent owner	- 15251	0.3 USD
6 years ago Nov 16, 2018	Sell 59 USD	Sikaria Lokesh 10 percent owner	- 200	0.2951 USD
6 years ago Nov 16, 2018	Sell 1.96 K USD	Sikaria Lokesh 10 percent owner	- 6657	0.295 USD
6 years ago Nov 16, 2018	Sell 544 USD	Sikaria Lokesh 10 percent owner	- 1850	0.294 USD
6 years ago Nov 16, 2018	Sell 17.2 K USD	Sikaria Lokesh 10 percent owner	- 58850	0.293 USD
6 years ago Nov 16, 2018	Sell 17.6 USD	Sikaria Chanda 10 percent owner	- 58	0.3028 USD
6 years ago Nov 16, 2018	Sell 452 USD	Sikaria Chanda 10 percent owner	- 1500	0.3011 USD
6 years ago Nov 16, 2018	Sell 455 USD	Sikaria Chanda 10 percent owner	- 1515	0.3006 USD
6 years ago Nov 16, 2018	Sell 4.24 K USD	Sikaria Chanda 10 percent owner	- 14119	0.3003 USD
6 years ago Nov 16, 2018	Sell 4.58 K USD	Sikaria Chanda 10 percent owner	- 15251	0.3 USD
6 years ago Nov 16, 2018	Sell 59 USD	Sikaria Chanda 10 percent owner	- 200	0.2951 USD
6 years ago Nov 16, 2018	Sell 1.96 K USD	Sikaria Chanda 10 percent owner	- 6657	0.295 USD
6 years ago Nov 16, 2018	Sell 544 USD	Sikaria Chanda 10 percent owner	- 1850	0.294 USD
6 years ago Nov 16, 2018	Sell 17.2 K USD	Sikaria Chanda 10 percent owner	- 58850	0.293 USD
6 years ago Nov 16, 2018	Sell 17.6 USD	Lokesh Sikaria Trust Dated 12/14/2012 10 percent owner	- 58	0.3028 USD
6 years ago Nov 16, 2018	Sell 452 USD	Lokesh Sikaria Trust Dated 12/14/2012 10 percent owner	- 1500	0.3011 USD
6 years ago Nov 16, 2018	Sell 455 USD	Lokesh Sikaria Trust Dated 12/14/2012 10 percent owner	- 1515	0.3006 USD
6 years ago Nov 16, 2018	Sell 4.24 K USD	Lokesh Sikaria Trust Dated 12/14/2012 10 percent owner	- 14119	0.3003 USD
6 years ago Nov 16, 2018	Sell 4.58 K USD	Lokesh Sikaria Trust Dated 12/14/2012 10 percent owner	- 15251	0.3 USD
6 years ago Nov 16, 2018	Sell 59 USD	Lokesh Sikaria Trust Dated 12/14/2012 10 percent owner	- 200	0.2951 USD
6 years ago Nov 16, 2018	Sell 1.96 K USD	Lokesh Sikaria Trust Dated 12/14/2012 10 percent owner	- 6657	0.295 USD
6 years ago Nov 16, 2018	Sell 544 USD	Lokesh Sikaria Trust Dated 12/14/2012 10 percent owner	- 1850	0.294 USD
6 years ago Nov 16, 2018	Sell 17.2 K USD	Lokesh Sikaria Trust Dated 12/14/2012 10 percent owner	- 58850	0.293 USD
6 years ago Nov 16, 2018	Sell 17.6 USD	Sikaria Family 2008 Revocable Trust Dated 02/28/2008 10 percent owner	- 58	0.3028 USD
6 years ago Nov 16, 2018	Sell 452 USD	Sikaria Family 2008 Revocable Trust Dated 02/28/2008 10 percent owner	- 1500	0.3011 USD
6 years ago Nov 16, 2018	Sell 455 USD	Sikaria Family 2008 Revocable Trust Dated 02/28/2008 10 percent owner	- 1515	0.3006 USD
6 years ago Nov 16, 2018	Sell 4.24 K USD	Sikaria Family 2008 Revocable Trust Dated 02/28/2008 10 percent owner	- 14119	0.3003 USD
6 years ago Nov 16, 2018	Sell 4.58 K USD	Sikaria Family 2008 Revocable Trust Dated 02/28/2008 10 percent owner	- 15251	0.3 USD
6 years ago Nov 16, 2018	Sell 59 USD	Sikaria Family 2008 Revocable Trust Dated 02/28/2008 10 percent owner	- 200	0.2951 USD
6 years ago Nov 16, 2018	Sell 1.96 K USD	Sikaria Family 2008 Revocable Trust Dated 02/28/2008 10 percent owner	- 6657	0.295 USD
6 years ago Nov 16, 2018	Sell 544 USD	Sikaria Family 2008 Revocable Trust Dated 02/28/2008 10 percent owner	- 1850	0.294 USD
6 years ago Nov 16, 2018	Sell 17.2 K USD	Sikaria Family 2008 Revocable Trust Dated 02/28/2008 10 percent owner	- 58850	0.293 USD
6 years ago Jun 07, 2018	Sell 661 K USD	Devanur Giri 10 percent owner	- 329357	2.0079 USD
6 years ago Jul 17, 2018	Sell 227 K USD	Devanur Giri 10 percent owner	- 100000	2.2663 USD
6 years ago Jun 12, 2018	Bought 6.75 K USD	Devanur Giri 10 percent owner	+ 25000	0.27 USD
7 years ago Nov 17, 2017	Bought 49.9 K USD	Devanur Giri President & CEO	+ 12121	4.115 USD
7 years ago Nov 17, 2017	Bought 49.9 K USD	Devanur Giri President & CEO	+ 12121	4.115 USD
7 years ago Nov 17, 2017	Bought 412 K USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 100000	4.115 USD
7 years ago Nov 17, 2017	Bought 412 K USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 100000	4.115 USD
7 years ago Nov 17, 2017	Bought 599 K USD	Rai Dhruwa N Director	+ 145450	4.115 USD
7 years ago Nov 17, 2017	Bought 599 K USD	Rai Dhruwa N Director	+ 145450	4.115 USD
7 years ago Oct 30, 2017	Bought 8.47 K USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 1303	6.4994 USD
7 years ago Oct 27, 2017	Bought 16.2 K USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 2500	6.5 USD
7 years ago Sep 06, 2017	Bought 48.8 K USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 7500	6.5 USD
7 years ago Aug 21, 2017	Bought 16.9 K USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 2604	6.4994 USD
7 years ago Mar 30, 2017	Bought 1.45 K USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 223	6.51 USD
7 years ago Mar 02, 2017	Bought 0 USD	Rai Dhruwa N Director	+ 0	0 USD
7 years ago Feb 10, 2017	Bought 2.83 K USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 434	6.51 USD
7 years ago Jan 23, 2017	Bought 13.9 K USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 2130	6.51 USD
7 years ago Jan 18, 2017	Bought 65.1 K USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 10000	6.51 USD
7 years ago Dec 30, 2016	Bought 260 USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 40	6.51 USD
7 years ago Dec 29, 2016	Bought 4.6 K USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 706	6.51 USD
7 years ago Dec 28, 2016	Bought 5.21 K USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 800	6.51 USD
7 years ago Dec 22, 2016	Bought 4.56 K USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 700	6.51 USD
7 years ago Dec 02, 2016	Bought 6.51 USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 1	6.51 USD
7 years ago Nov 30, 2016	Bought 5.25 K USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 807	6.51 USD
8 years ago Oct 20, 2016	Bought 820 USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 126	6.51 USD
8 years ago Oct 19, 2016	Bought 2.6 K USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 400	6.51 USD
8 years ago Sep 26, 2016	Bought 1.19 K USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 183	6.51 USD
8 years ago Sep 02, 2016	Bought 3.07 K USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 471	6.51 USD
8 years ago Sep 01, 2016	Bought 119 K USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 18214	6.51 USD
8 years ago Aug 31, 2016	Bought 6.59 K USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 1013	6.51 USD
8 years ago Aug 29, 2016	Bought 527 USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 81	6.51 USD
8 years ago Aug 25, 2016	Bought 326 USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 50	6.51 USD
8 years ago Aug 24, 2016	Bought 2.6 K USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 400	6.5075 USD
8 years ago Aug 22, 2016	Bought 169 USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 26	6.51 USD
8 years ago Aug 19, 2016	Bought 5.84 K USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 897	6.51 USD
8 years ago Aug 19, 2016	Bought 550 USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 100	5.5 USD
8 years ago Aug 09, 2016	Bought 807 USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 124	6.51 USD
8 years ago Jul 27, 2016	Bought 671 USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 103	6.51 USD
8 years ago Jul 25, 2016	Bought 2.01 K USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 308	6.51 USD
8 years ago Jul 12, 2016	Bought 1.3 K USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 200	6.51 USD
8 years ago Jul 06, 2016	Bought 5.6 K USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 860	6.51 USD
8 years ago Jul 01, 2016	Bought 3.26 K USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 500	6.51 USD
8 years ago Jun 28, 2016	Bought 182 USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 28	6.51 USD
8 years ago Jun 14, 2016	Bought 547 USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 84	6.51 USD
8 years ago Jun 13, 2016	Bought 6.51 K USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 1000	6.51 USD
8 years ago Jun 06, 2016	Bought 2.04 K USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 314	6.51 USD
8 years ago Jun 03, 2016	Bought 58.6 USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 9	6.51 USD
8 years ago Jun 02, 2016	Bought 3.13 K USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 481	6.51 USD
8 years ago May 18, 2016	Bought 651 USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 100	6.51 USD
8 years ago Apr 20, 2016	Bought 475 USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 73	6.51 USD
8 years ago Apr 19, 2016	Bought 474 USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 73	6.5 USD
8 years ago Apr 18, 2016	Bought 475 USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 73	6.51 USD
8 years ago Apr 13, 2016	Bought 365 USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 56	6.51 USD
8 years ago Apr 12, 2016	Bought 365 USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 56	6.51 USD
8 years ago Apr 04, 2016	Bought 284 USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 44	6.45 USD
8 years ago Mar 31, 2016	Bought 267 USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 41	6.51 USD
8 years ago Mar 28, 2016	Bought 365 USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 56	6.51 USD
8 years ago Mar 30, 2016	Bought 45.6 USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 7	6.51 USD
8 years ago Mar 28, 2016	Bought 417 USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 64	6.51 USD
8 years ago Feb 05, 2016	Bought 534 USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 89	6 USD
8 years ago Feb 02, 2016	Bought 15.6 K USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 2600	6.01 USD
8 years ago Jan 08, 2016	Bought 25.4 K USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 4220	6.01 USD
8 years ago Jan 07, 2016	Bought 6.51 K USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 1084	6.01 USD
8 years ago Dec 18, 2015	Bought 6.43 K USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 1070	6.01 USD
8 years ago Dec 17, 2015	Bought 41.8 K USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 6962	6.01 USD
8 years ago Dec 16, 2015	Bought 59.7 K USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 9931	6.01 USD
8 years ago Dec 15, 2015	Bought 4.21 K USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 700	6.01 USD
8 years ago Dec 14, 2015	Bought 3 K USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 500	6.01 USD
8 years ago Dec 11, 2015	Bought 349 USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 58	6.01 USD
8 years ago Dec 10, 2015	Bought 10.6 K USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 1759	6.01 USD
8 years ago Dec 09, 2015	Bought 6.01 K USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 1000	6.01 USD
9 years ago Jul 16, 2015	Bought 1.87 K USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 1249	1.5 USD
9 years ago Jul 13, 2015	Bought 6.27 K USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 2500	2.51 USD
9 years ago Jul 08, 2015	Bought 3.43 K USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 1368	2.51 USD
9 years ago Jul 02, 2015	Bought 24 USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 12	2 USD
9 years ago Jun 18, 2015	Bought 2.51 USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 1	2.51 USD
9 years ago Jun 15, 2015	Bought 12.1 K USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 5000	2.4288 USD
9 years ago May 26, 2015	Bought 5 M USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 2777777	1.8 USD
9 years ago May 26, 2015	Bought 0 USD	Eberwein Jeffrey E. director, 10 percent owner:	+ 0	1.8 USD
10 years ago Jan 15, 2014	Bought 50 K USD	Eberwein Jeffrey E. Chairman, President, CEO, CFO	+ 3267974	0.0153 USD
12 years ago Jul 25, 2012	Sell 17.8 K USD	SCHNEIDER GREGGORY A Chief Financial Officer	- 713527	0.025 USD
13 years ago Aug 25, 2011	Bought 36.2 K USD	SCHNEIDER GREGGORY A Chief Financial Officer	+ 2334516	0.0155 USD
13 years ago Aug 25, 2011	Bought 51.3 K USD	GOTTLIEB JAY Chief Executive Officer	+ 3307484	0.0155 USD
15 years ago Sep 25, 2009	Bought 0 USD	GOTTLIEB JAY Chief Executive Officer	+ 0	0 USD
15 years ago Sep 25, 2009	Bought 0 USD	SCHNEIDER GREGGORY A Chief Financial Officer	+ 0	0 USD
15 years ago Jul 07, 2009	Bought 15.1 K USD	GOTTLIEB JAY Chief Executive Officer	+ 5584615	0.0027 USD
15 years ago Jul 07, 2009	Bought 12.2 K USD	SCHNEIDER GREGGORY A Chief Financial Officer	+ 4505000	0.0027 USD
20 years ago Nov 28, 2003	Sell 6.15 K USD	MANDELL HENRY R Chairman/CEO/CFO/Secretary	- 30000	0.205 USD
20 years ago Nov 28, 2003	Sell 2 K USD	MANDELL HENRY R Chairman/CEO/CFO/Secretary	- 10000	0.2 USD
20 years ago Nov 28, 2003	Sell 1.47 K USD	MANDELL HENRY R Chairman/CEO/CFO/Secretary	- 7000	0.21 USD
20 years ago Nov 28, 2003	Sell 1.7 K USD	MANDELL HENRY R Chairman/CEO/CFO/Secretary	- 10000	0.17 USD
20 years ago Dec 01, 2003	Sell 2 K USD	MANDELL HENRY R Chairman/CEO/CFO/Secretary	- 10000	0.2 USD
20 years ago Dec 01, 2003	Sell 2.85 K USD	MANDELL HENRY R Chairman/CEO/CFO/Secretary	- 15000	0.19 USD
20 years ago Dec 01, 2003	Sell 5.55 K USD	MANDELL HENRY R Chairman/CEO/CFO/Secretary	- 30000	0.185 USD
20 years ago Dec 01, 2003	Sell 6.98 K USD	MANDELL HENRY R Chairman/CEO/CFO/Secretary	- 45000	0.155 USD
20 years ago Dec 01, 2003	Sell 800 USD	MANDELL HENRY R Chairman/CEO/CFO/Secretary	- 5000	0.16 USD
20 years ago Dec 01, 2003	Sell 725 USD	MANDELL HENRY R Chairman/CEO/CFO/Secretary	- 5000	0.145 USD
20 years ago Dec 01, 2003	Sell 770 USD	MANDELL HENRY R Chairman/CEO/CFO/Secretary	- 5000	0.154 USD
20 years ago Dec 01, 2003	Sell 1.8 K USD	MANDELL HENRY R Chairman/CEO/CFO/Secretary	- 10000	0.18 USD
20 years ago Dec 01, 2003	Sell 3.45 K USD	MANDELL HENRY R Chairman/CEO/CFO/Secretary	- 23000	0.15 USD
20 years ago Nov 28, 2003	Sell 6.15 K USD	MANDELL HENRY R Chief Executive Officer	- 30000	0.205 USD
20 years ago Nov 28, 2003	Sell 2 K USD	MANDELL HENRY R Chief Executive Officer	- 10000	0.2 USD
20 years ago Nov 28, 2003	Sell 1.47 K USD	MANDELL HENRY R Chief Executive Officer	- 7000	0.21 USD
20 years ago Nov 28, 2003	Sell 1.7 K USD	MANDELL HENRY R Chief Executive Officer	- 10000	0.17 USD
20 years ago Dec 01, 2003	Sell 2 K USD	MANDELL HENRY R Chief Executive Officer	- 10000	0.2 USD
20 years ago Dec 01, 2003	Sell 2.85 K USD	MANDELL HENRY R Chief Executive Officer	- 15000	0.19 USD
20 years ago Dec 01, 2003	Sell 5.55 K USD	MANDELL HENRY R Chief Executive Officer	- 30000	0.185 USD
20 years ago Dec 01, 2003	Sell 6.98 K USD	MANDELL HENRY R Chief Executive Officer	- 45000	0.155 USD
20 years ago Dec 01, 2003	Sell 800 USD	MANDELL HENRY R Chief Executive Officer	- 5000	0.16 USD
20 years ago Dec 01, 2003	Sell 725 USD	MANDELL HENRY R Chief Executive Officer	- 5000	0.145 USD
20 years ago Dec 01, 2003	Sell 770 USD	MANDELL HENRY R Chief Executive Officer	- 5000	0.154 USD
20 years ago Dec 01, 2003	Sell 1.8 K USD	MANDELL HENRY R Chief Executive Officer	- 10000	0.18 USD
20 years ago Dec 01, 2003	Sell 3.45 K USD	MANDELL HENRY R Chief Executive Officer	- 23000	0.15 USD
20 years ago Dec 01, 2003	Sell 6 K USD	MANDELL HENRY R Chief Executive Officer	- 50000	0.12 USD

7. News

Enveric Biosciences Announces Broad Range of Patent Issuances CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogens for the treatment of neuropsychiatric disorders, today announces the expansion of patent protection for a broad range of molecules in its EVM301 portfolio through the issuance of five additional US patents and the recent allowance of three more patent applications by the United States Patent and Trademark Office. The U. businesswire.com - 1 week ago

Enveric Biosciences Presents Data Highlighting Development of EB-003 at European Behavioral Pharmacology Society Biennial Workshop CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that it is presenting research describing the Company's identification of EB-003 as its lead development candidate based on preclinical data suggesting the compound exhibits promising anxiolytic and anti-depre. businesswire.com - 1 month ago

Enveric Biosciences Presents Data on Lead Product Candidate, EB-003, at 7th Neuropsychiatric Drug Summit CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that research highlighting the Company's lead compound, EB-003, is being presented at the 7th Neuropsychiatric Drug Summit. EB-003 is a promising neuroplastogenic and non-hallucinogenic N,N-Dimethyltryptamine. businesswire.com - 1 month ago

Enveric Biosciences Reports Second Quarter 2024 Financial and Corporate Results CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today provided a corporate update and reported financial results for the second quarter ended June 30, 2024. “The second quarter of 2024 was marked by the prioritization of EB-003 as our lead development candidate. This strat. businesswire.com - 3 months ago

Why Is Enveric Biosciences (ENVB) Stock Up 18% Today? Enveric Biosciences (NASDAQ: ENVB ) stock is heading higher on Tuesday alongside heavy pre-market trading of the biotechnology company's shares. This comes with more than 13 million shares of ENVB stock changing hands as of this writing. investorplace.com - 3 months ago

Diamond Equity Research Releases Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB) NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB). The update note includes information on the Enveric Bioscience's management commentary, recent developments, outlook, and risks. globenewswire.com - 4 months ago

Enveric Biosciences Provides Strategic Outlook and Pipeline Update, Elevating EB-003 to Lead Development Candidate CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced the Company is prioritizing the development of EB-003, its first-in-class approach to address difficult-to-treat mental health disorders. EB-003 and other neuroplastogens developed by Enveric are designed to p. businesswire.com - 4 months ago

Enveric Biosciences to Participate in BIO International Convention 2024 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that the Company will participate in the 2024 BIO International Convention taking place in San Diego, CA from June 3 – 6, 2024. During the conference, Enveric's management team plans to host meetings with pote. businesswire.com - 5 months ago

Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today provided a corporate update and reported financial results for the first quarter of 2024 ended March 31, 2024. “We believe the first quarter of 2024 was a highly productive period for Enveric as the Company continued to. businesswire.com - 6 months ago

Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders MindBio to develop the novel psilocin prodrug for neuropsychiatric indications utilizing microdosing to reduce or eliminate hallucinogenic impact of psychedelic compounds VANCOUVER, BC / ACCESSWIRE / May 14, 2024 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the "Company" or "MindBio"), a clinical stage biopharma company pioneering microdosing treatments for mental health conditions today announced that it has signed a non-binding term sheet to out-license a class of Novel Psilocin Prodrugs ("NPP") from Enveric Biosciences (ENVB), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. Enveric's NPP molecules are designed to be metabolized specifically to release therapeutic levels of systemic psilocin at varying rates. accesswire.com - 6 months ago

Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that it has signed a non-binding term sheet to out-license a class of Novel Psilocin Prodrugs (“NPP”) to Vancouver, BC-based MindBio Therapeutics (CNSX: MBIO)(“MindBio”), a clinical stage biopharma company, wh. businesswire.com - 6 months ago

Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc (NASDAQ: ENVB), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that it has signed a non-binding term sheet with an undisclosed biotechnology development and commercialization company (“Licensee”) to exclusively out-license two patent families of Methods for Treating Breast Cancer and Other Cance. businesswire.com - 6 months ago

8. Profile Summary

Enveric Biosciences, Inc. ENVB

COUNTRY US

INDUSTRY Biotechnology

MARKET CAP $ 3.26 M

Dividend Yield 0.00%

Description Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

Contact 4851 Tamiami Trail North, Naples, FL, 34103 https://www.enveric.com

IPO Date May 4, 2015

Employees 7

Officers Mr. Kevin M. Coveney CPA Chief Financial Officer Dr. Joseph Edward Tucker Ph.D. Chief Executive Officer & Director Dr. Peter J. Facchini Ph.D. Chief Innovation Officer

Price Chart ENVB

Enveric Biosciences, Inc. ENVB

Premium Plan

Unlimited Plan